JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias

Activating JAK2 point mutations are implicated in the pathogenesis of myeloid and lymphoid malignancies, including high-risk B-cell acute lymphoblastic leukemia (B-ALL). In preclinical studies, treatment of JAK2 mutant leukemias with type I JAK2 inhibitors (e.g., Food and Drug Administration [FDA]-approved ruxolitinib) provided limited single-agent responses, possibly due to paradoxical JAK2Y1007/1008 hyperphosphorylation induced by these agents. To determine the importance of mutant JAK2 in B-ALL initiation and maintenance, we developed unique genetically engineered mouse models of B-ALL driven by overexpressed Crlf2 and mutant Jak2, recapitulating the genetic aberrations found in human B-ALL. While expression of mutant Jak2 was necessary for leukemia induction, neither its continued expression nor enzymatic activity was required to maintain leukemia survival and rapid proliferation. CRLF2/JAK2 mutant B-ALLs with sustained depletion or pharmacological inhibition of JAK2 exhibited enhanced expression of c-Myc and prominent up-regulation of c-Myc target genes. Combined indirect targeting of c-Myc using the BET bromodomain inhibitor JQ1 and direct targeting of JAK2 with ruxolitinib potently killed JAK2 mutant B-ALLs.

[1]  M. D. Den Boer,et al.  JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia , 2016, Oncotarget.

[2]  C. Mullighan,et al.  Acute Lymphoblastic Leukemia in Children. , 2015, The New England journal of medicine.

[3]  A. Letai,et al.  Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. , 2015, Cancer cell.

[4]  Stephen Wilcox,et al.  An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. , 2015, Cell reports.

[5]  Heather L. Mulder,et al.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.

[6]  Jacob D. Jaffe,et al.  Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 lysine 27 trimethylation , 2014, Nature Genetics.

[7]  J. Qi,et al.  Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. , 2014, Blood.

[8]  S. Monti,et al.  Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo , 2014, Clinical Cancer Research.

[9]  R. Dickins,et al.  Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors , 2013, Cell reports.

[10]  Jessica E. Bolden,et al.  Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities , 2013, Molecular Cancer Therapeutics.

[11]  M. Loh,et al.  Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2012, Blood.

[12]  Christopher J. Ott,et al.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.

[13]  Ryan D. Morin,et al.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.

[14]  Julie M Gastier-Foster,et al.  Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. , 2012, Blood.

[15]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[16]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[17]  Eric Vangrevelinghe,et al.  Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition , 2011, The Journal of experimental medicine.

[18]  B. Bernstein,et al.  Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy , 2011, Nature.

[19]  D. Erdmann,et al.  Genetic resistance to JAK 2 enzymatic inhibitors is overcome by HSP 90 inhibition , 2012 .

[20]  M. Loh,et al.  Aberrant STAT 5 and PI 3 K / mTOR pathway signaling occurs in human CRLF 2-rearranged B-precursor acute lymphoblastic leukemia , 2012 .

[21]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[22]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[23]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[24]  Christof Fellmann,et al.  Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi , 2011, Nature Biotechnology.

[25]  C. Schwab,et al.  Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood. 2011; 117(7):2129-2136 , 2011 .

[26]  Takashi Akasaka,et al.  Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. , 2010, Blood.

[27]  J. Downing,et al.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.

[28]  E. Domany,et al.  Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. , 2010, Blood.

[29]  E. Domany,et al.  Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. , 2010, Blood.

[30]  J. Downing,et al.  Rearrangement of CRLF 2 is associated with mutation of JAK kinases , alteration of IKZF 1 , Hispanic / Latino ethnicity , and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia * , 2010 .

[31]  J. Downing,et al.  Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia , 2009, Nature Genetics.

[32]  Takashi Akasaka,et al.  Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.

[33]  M. Loh,et al.  JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[34]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[35]  J. Downing,et al.  Rearrangement of CRLF 2 in B-progenitor – and Down syndrome – associated acute lymphoblastic leukemia , 2009 .

[36]  Sandra A. Moore,et al.  Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. , 2008, Cancer cell.

[37]  G. Noronha,et al.  Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. , 2008, Cancer cell.

[38]  B. Lüscher,et al.  The Ins and Outs of MYC Regulation by Posttranslational Mechanisms* , 2006, Journal of Biological Chemistry.

[39]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[40]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[41]  Ernest Martinez,et al.  Dual Regulation of c-Myc by p300 via Acetylation-Dependent Control of Myc Protein Turnover and Coactivation of Myc-Induced Transcription , 2005, Molecular and Cellular Biology.

[42]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[44]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[45]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[46]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[47]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[48]  H. Yost,et al.  Protein phosphatase 2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus , 2001, The EMBO journal.

[49]  J.M. Adams,et al.  Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. , 1994, The EMBO journal.

[50]  R. Hardy,et al.  The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver , 1993, The Journal of experimental medicine.

[51]  D. Baltimore,et al.  Virus-transformed pre-B cells show ordered activation but not inactivation of immunoglobulin gene rearrangement and transcription , 1991, The Journal of experimental medicine.

[52]  M. Greaves,et al.  Immunoglobulin gene organisation and expression in haemopoietic stem cell leukaemia. , 1983, The EMBO journal.